XML 17 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 24, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Entity Registrant Name XENON PHARMACEUTICALS INC.    
Current Fiscal Year End Date --12-31    
Entity Common Stock, Shares Outstanding   76,542,811  
Entity Public Float     $ 2,946.2
Amendment Flag false    
Trading Symbol XENE    
Entity Central Index Key 0001582313    
Document Annual Report true    
Document Transition Report false    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Large Accelerated Filer    
Entity Well-known Seasoned Issuer Yes    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Document Financial Statement Error Correction [Flag] true    
Document Financial Statement Restatement Recovery Analysis [Flag] false    
Entity Shell Company false    
Entity Small Business false    
Entity Emerging Growth Company false    
Title of 12(b) Security Common Shares, without par value    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Entity Tax Identification Number 98-0661854    
Entity Address, Address Line One 200-3650 Gilmore Way    
Entity Address, City or Town Burnaby    
Entity Address, State or Province BC    
City Area Code 604    
Local Phone Number 484-3300    
Entity File Number 001-36687    
Entity Address, Postal Zip Code V5G 4W8    
Entity Incorporation, State or Country Code Z4    
Entity Address, Country CA    
ICFR Auditor Attestation Flag true    
Auditor Name KPMG LLP    
Auditor Firm ID 85    
Auditor Location Vancouver, BC, Canada    
Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement relating to the 2024 Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission subsequent to the date hereof, are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant’s fiscal year ended December 31, 2024.

   
Auditor Opinion [Text Block]

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Xenon Pharmaceuticals Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2024 and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2025 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.